Journal of Advances in Drug Research

ISSN: 2230-7761
www.jadr.co.in

Volume 17, Issue 04 | Received 18.09.2026 | Accepted 19.09.2026 | Online 23.09.2026

BEHAVIORAL PHARMACOLOGY OF ANTIDEPRESSANT AND ANXIOLYTIC AGENTS

Anna K. Hoffmann
Department of Pharmacology and Drug Discovery,
Rhine Biomedical Research Institute, Germany
anna.hoffmann@rbri-med.de

Abstract

Behavioral pharmacology provides an essential bridge between molecular drug action and clinically meaningful changes in mood, anxiety, motivation, stress coping, and cognition. This structured review synthesizes evidence on the behavioral and mechanistic profiles of major antidepressant and anxiolytic drug classes, with emphasis on monoaminergic antidepressants, benzodiazepines and other GABAergic modulators, 5-HT1A agonists, and rapid-acting glutamatergic antidepressants. A targeted literature synthesis was conducted using peer-reviewed international sources, prioritizing contemporary mechanistic reviews, translational studies, and methodological analyses of behavioral models. The evidence indicates that selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs) exert delayed behavioral effects that depend on downstream neuroadaptation, while benzodiazepines produce rapid anxiolysis through positive allosteric modulation of GABA-A receptors but are limited by sedation, tolerance, and dependence. Ketamine and esketamine demonstrate a distinct rapid-acting profile involving NMDA-receptor blockade, AMPA-dependent synaptic potentiation, BDNF-related plasticity, and network-level resetting. Preclinical behavioral assays remain valuable for screening but require careful interpretation because single tests may capture coping, locomotion, exploration, or reward processes rather than discrete psychiatric diagnoses. The most informative strategy combines multiple behavioral domains with mechanistic biomarkers and clinically relevant outcome measures. Future behavioral pharmacology is likely to rely on circuit-resolved phenotyping, digital behavioral markers, sex-aware models, and mechanism-based patient stratification to improve translation from experimental findings to individualized therapy.

Keywords: behavioral pharmacology; antidepressants; anxiolytics; SSRIs; benzodiazepines; ketamine; GABA-A receptor; serotonin; anxiety; depression

1. INTRODUCTION

Major depressive disorder and anxiety disorders are among the most prevalent neuropsychiatric conditions and are major contributors to disability, impaired functioning, and reduced quality of life. Pharmacotherapy remains a central component of treatment, yet individual response is heterogeneous and the onset, magnitude, and tolerability of benefit differ substantially among drug classes. Behavioral pharmacology examines how pharmacological manipulation of neurotransmitter systems, receptors, intracellular

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 18.09.2026 Accepted 19.09.2026 Online 23.09.2026

signaling pathways, and neural circuits is expressed as measurable changes in behavior. This field is therefore crucial for linking molecular mechanisms to therapeutic response and for identifying limitations that may not be visible in receptor-binding or biochemical assays alone (1,2).

Classical antidepressant development was dominated by the monoamine framework, leading to the use of SSRIs, SNRIs, tricyclic antidepressants, and monoamine oxidase inhibitors. Although these agents alter monoamine transmission rapidly at the molecular level, clinically relevant improvement generally requires repeated administration, supporting the view that neuroadaptive processes, synaptic plasticity, stress-circuit remodeling, and downstream transcriptional effects are important components of antidepressant action (3,4). In contrast, benzodiazepines can reduce anxiety rapidly by enhancing GABA-A receptor function, but this speed is accompanied by risks such as sedation, psychomotor impairment, tolerance, and dependence (5,6).

Rapid-acting antidepressants have changed the conceptual landscape. Ketamine and esketamine can produce clinically meaningful antidepressant effects within hours in some patients, highlighting glutamatergic signaling, AMPA-mediated transmission, BDNF-dependent plasticity, mTOR-related pathways, and neural-circuit reconfiguration as important therapeutic mechanisms (7-9). These advances show that behavioral outcomes can arise from pharmacological pathways that differ markedly in time course and molecular architecture.

The objective of this article is to summarize the principal behavioral pharmacology of antidepressant and anxiolytic agents, compare major pharmacological classes, evaluate commonly used behavioral models, and identify translational principles that can improve the predictive value of experimental pharmacology.

2. MATERIALS AND METHODS

This article was designed as a structured evidence-based literature review using an IMRAD format. Peer-reviewed international publications were identified from PubMed-indexed literature and major pharmacology and neuropsychopharmacology journals. Priority was given to mechanistic reviews, translational studies, systematic evaluations of behavioral tests, and clinically relevant pharmacology published from 2018 to 2026, with selected foundational studies retained when they remained central to the interpretation of behavioral models or receptor pharmacology.

Key concepts included antidepressant behavioral pharmacology, anxiolytic behavioral pharmacology, SSRI and SNRI mechanisms, GABA-A receptor modulation, benzodiazepines, 5-HT1A agonists, ketamine and esketamine, forced swim test, tail suspension test, elevated plus maze, open-field test, light-dark box, sucrose preference, and translational validity. Evidence was synthesized qualitatively because the included sources differed substantially in experimental design, species, endpoints, and treatment duration. Particular attention was paid to construct validity, predictive validity, potential locomotor confounding, onset of action, and known clinical limitations. No new animal or human experiment was performed.

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 18.09.2026 Accepted 19.09.2026 Online 23.09.2026

3. RESULTS

3.1. Monoaminergic antidepressants and adaptive behavioral change

SSRIs increase extracellular serotonin by inhibiting the serotonin transporter, whereas SNRIs inhibit both serotonin and norepinephrine transporters. Acute transporter inhibition occurs rapidly, but therapeutic behavioral improvement usually develops over repeated dosing. This delay is consistent with changes in autoreceptor sensitivity, gene expression, neurotrophic signaling, synaptic remodeling, and circuit adaptation rather than a simple direct relationship between synaptic monoamine concentration and mood (3,4). Behavioral models often show stronger antidepressant-like effects after repeated administration, particularly in paradigms that assess stress coping, reward sensitivity, or chronic stress-induced deficits.

In preclinical screening, the forced swim test and tail suspension test have been widely used because many established antidepressants reduce immobility. However, current methodological interpretation emphasizes that immobility should not be equated with a depressive state; it may reflect a coping strategy in an inescapable context. Consequently, these tests are best treated as pharmacologically sensitive screening paradigms rather than standalone models of depression (10,11). Reward-related assays, including sucrose preference, and chronic stress paradigms can provide complementary information about anhedonia and stress adaptation.

3.2. GABAergic anxiolysis and benzodiazepine-related behavioral effects

Benzodiazepines are positive allosteric modulators of GABA-A receptors and rapidly increase inhibitory neurotransmission. Their characteristic behavioral profile includes reduced avoidance and threat-related behavior, but also dose-dependent sedation, impaired coordination, reduced exploration, and memory effects. These confounds are particularly important in rodent tests because a decrease in locomotion can mimic or obscure changes in anxiety-like behavior. Modern interpretation therefore requires parallel assessment of spontaneous activity and motor performance (5,6).

Behavioral tests commonly used for anxiolytic screening include the elevated plus maze, light-dark box, open-field test, social interaction test, and novelty-suppressed feeding. Meta-analytic work has shown that test reliability and drug sensitivity vary across laboratories, strains, and protocols, reinforcing the need for replication and multi-test batteries rather than reliance on one outcome (12). The therapeutic value of GABA-A modulation remains substantial, but the search for subtype-selective modulators aims to retain anxiolysis while reducing sedation, tolerance, and abuse liability (6).

3.3. 5-HT1A mechanisms and non-benzodiazepine anxiolytic strategies

Buspirone and related 5-HT1A partial agonists offer a non-benzodiazepine approach to anxiety treatment. Their behavioral profile differs from that of benzodiazepines: onset is slower, sedation and dependence are lower, and effects are mediated through serotonergic

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 18.09.2026 Accepted 19.09.2026 Online 23.09.2026

autoreceptor and postsynaptic mechanisms. In experimental paradigms, serotonergic anxiolysis can be sensitive to baseline stress state and test conditions, and clinical efficacy may be more modest or diagnosis-specific than the immediate effects observed with benzodiazepines. Current pharmacotherapy therefore often uses SSRIs or SNRIs as first-line long-term agents, with acute GABAergic treatment reserved for selected situations (13).

Table 1. Major antidepressant and anxiolytic drug classes in behavioral pharmacology

Drug class	Primary target	Behavioral pharmacology	Key limitation
SSRIs	SERT inhibition; ↑ 5-HT	Reduced stress-related and anxiety-like responses after repeated dosing	Delayed onset; activation, sexual adverse effects
SNRIs	SERT + NET inhibition	Antidepressant and anxiolytic effects; improved stress coping	Delayed onset; BP/adrenergic adverse effects in some patients
Benzodiazepines	GABA-A positive allosteric modulation	Rapid reduction of avoidance/threat behavior	Sedation, psychomotor impairment, tolerance, dependence
Buspirone	5-HT1A partial agonism	Anxiolytic profile without strong sedative effects	Slower onset; variable efficacy across anxiety phenotypes
Ketamine / Esketamine	NMDA antagonism; AMPA/plasticity signaling	Rapid antidepressant-like effects; restored stress-related behavior	Dissociation, BP elevation, monitoring requirements
Neurosteroid GABA modulators	GABA-A modulation, including extrasynaptic receptors	Rapid modulation of affective and stress-related behavior	Sedation/somnolence; indication-specific use

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 18.09.2026 Accepted 19.09.2026 Online 23.09.2026

Major pharmacological routes linking molecular targets to behavioral and clinical effects




Figure 1. Major molecular routes linking antidepressant and anxiolytic drug action to behavioral and clinical response.

3.4. Rapid-acting glutamatergic antidepressants

Ketamine has provided one of the clearest demonstrations that antidepressant behavioral effects do not require prolonged monoamine manipulation. Subanesthetic ketamine blocks NMDA receptors and initiates downstream changes that can enhance AMPA-receptor throughput, BDNF-related signaling, synaptic protein synthesis, and functional connectivity in mood-regulating networks (7-9). Contemporary work also emphasizes interactions with GABAergic interneurons, neuroimmune pathways, astrocytes, and metaplasticity mechanisms (7,8).

From a behavioral perspective, ketamine can reverse stress-induced deficits and reduce passive coping in animal models within a short time frame. However, interpretation requires attention to locomotor stimulation, dissociative-like effects, and the fact that acute behavioral normalization does not automatically predict durable clinical remission. The translational significance of ketamine is therefore strongest when behavioral data are integrated with synaptic, molecular, and circuit-level endpoints.

3.5. Behavioral-model validity and translational integration

No single behavioral test reproduces the complexity of human depression or anxiety. The elevated plus maze primarily indexes approach-avoidance conflict, open-field behavior combines exploration and locomotion, sucrose preference is frequently used as an index of reward sensitivity, and the forced swim test is more appropriately interpreted as stress-coping behavior than as a direct measure of depression (10-12). This distinction is important because pharmacological effects on movement, arousal, appetite, pain, or cognition can alter test performance independently of therapeutic mechanisms.

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 18.09.2026 Accepted 19.09.2026 Online 23.09.2026

The most robust behavioral pharmacology strategy is therefore a convergent battery. A candidate antidepressant may be evaluated in stress-coping and reward-related paradigms, while a candidate anxiolytic should be examined across approach-avoidance tests together with locomotor and sedative controls. Chronic stress models can then assess whether the drug restores disrupted behavior over time. Mechanistic confirmation using receptor occupancy, signaling biomarkers, electrophysiology, or neuroimaging improves causal interpretation.

Table 2. Common behavioral assays and interpretation in antidepressant/anxiolytic pharmacology

Assay	Primary construct	Strength	Important limitation
Forced swim / tail suspension	Stress coping / immobility	Sensitive to many antidepressants	Not a direct model of depression; locomotor confounding
Elevated plus maze	Approach-avoidance conflict	Sensitive to several anxiolytics	Exploration, strain, lighting and sedation affect outcome
Light-dark box	Avoidance of illuminated space	Useful for anxiolytic screening	Locomotor changes may alter transitions
Open-field test	Exploration + locomotion + center avoidance	Useful as anxiolysis plus motor control	Highly context-sensitive; weak specificity
Sucrose preference	Reward sensitivity / anhedonia-like behavior	Useful after chronic stress	Influenced by appetite, taste, metabolic state
Novelty-suppressed feeding	Conflict between hunger and novelty	Sensitive to chronic antidepressant/anxiolytic effects	Requires careful control of feeding and body weight

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 18.09.2026 Accepted 19.09.2026 Online 23.09.2026



Figure 2. Integrated behavioral pharmacology workflow for antidepressant and anxiolytic drug development.

4. DISCUSSION

The reviewed evidence demonstrates that antidepressant and anxiolytic drugs can produce superficially similar behavioral outcomes through markedly different molecular mechanisms and time courses. Monoaminergic antidepressants are characterized by delayed behavioral normalization that appears to depend on cumulative neuroadaptation, whereas benzodiazepines produce immediate suppression of anxiety-related behavior through enhanced inhibitory transmission. Ketamine represents a third pattern in which rapid synaptic and circuit plasticity can generate antidepressant effects on a time scale previously considered unlikely for pharmacotherapy (3,5,7).

These differences have practical implications for experimental design. A drug that reduces immobility or avoidance after one dose may reflect true therapeutic action, nonspecific stimulation, sedation, altered arousal, or changes in motor capacity. Likewise, a compound that fails in an acute test may still be effective after repeated treatment if its mechanism depends on receptor desensitization, transcriptional adaptation, or synaptic remodeling. Behavioral pharmacology therefore requires matching the assay time frame to the expected pharmacodynamic mechanism.

Another major issue is construct validity. Behavioral tests model dimensions of psychopathology rather than complete human diagnoses. The forced swim test, for example, is pharmacologically sensitive but should not be interpreted as an animal equivalent of human depression. Similarly, elevated plus maze performance represents an approach-avoidance decision influenced by anxiety, exploration, sensory conditions, and

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 18.09.2026 Accepted 19.09.2026 Online 23.09.2026

motor function. Methodological reviews increasingly recommend battery-based designs, transparent reporting, replication, and attention to sex, strain, housing, prior stress, circadian timing, and experimenter effects (10-12).

Future progress will likely depend on combining conventional behavioral pharmacology with high-resolution circuit and biomarker approaches. Automated home-cage phenotyping, machine-learning analysis of movement and posture, wearable and digital behavioral markers in clinical studies, receptor-specific imaging, and pharmacogenomic or biomarker-guided stratification may help align preclinical endpoints with patient phenotypes. New GABA-A subtype-selective modulators, neurosteroid agents, glutamatergic compounds, psychedelic-related therapeutics, and agents targeting neuroimmune or synaptic plasticity pathways may further expand the mechanistic diversity of treatment (6-9,14,15).

5. CONCLUSION

Behavioral pharmacology remains a fundamental component of antidepressant and anxiolytic drug development because it connects receptor-level action to integrated organism-level outcomes. SSRIs and SNRIs primarily depend on delayed neuroadaptive mechanisms, benzodiazepines provide rapid GABAergic anxiolysis with important safety limitations, 5-HT1A agonists offer a slower non-sedative anxiolytic profile, and ketamine demonstrates that rapid antidepressant effects can emerge through glutamatergic and synaptic-plasticity mechanisms. The predictive value of experimental models improves when multiple behavioral domains are assessed alongside motor, cognitive, molecular, and circuit-level controls. Future therapeutic discovery should move from single-test screening toward multidimensional phenotyping and mechanism-based translation, thereby improving the probability that behavioral effects observed experimentally correspond to meaningful and durable clinical benefit.

REFERENCES

1. Stahl, S. M. (2021). Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications (5th ed.). Cambridge University Press.
2. Duman, R. S., & Aghajanian, G. K. (2012). Synaptic dysfunction in depression: Potential therapeutic targets. Science, 338(6103), 68-72.
3. Harmer, C. J., Duman, R. S., & Cowen, P. J. (2017). How do antidepressants work? New perspectives for refining future treatment approaches. The Lancet Psychiatry, 4(5), 409-418.
4. Cui, L., Li, S., Wang, S., et al. (2024). Major depressive disorder: hypothesis, mechanism, prevention and treatment. Signal Transduction and Targeted Therapy, 9, 30.
5. Möhler, H. (2012). The GABA system in anxiety and depression and its therapeutic potential. Neuropharmacology, 62(1), 42-53.
6. Zhang, Y., et al. (2024). Clinical applications of small-molecule GABA-A receptor modulators for neurological disorders. Bioorganic Chemistry, 153, 107983.

Journal of Advances in Drug Research

ISSN: 2230-7761
www.jadr.co.in

Volume 17, Issue 04 | Received 18.09.2026 | Accepted 19.09.2026 | Online 23.09.2026

7. Krystal, J. H., Kavalali, E. T., & Monteggia, L. M. (2024). Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms. Neuropsychopharmacology, 49, 41-50.
8. Kim, J.-W., Suzuki, K., Kavalali, E. T., & Monteggia, L. M. (2024). Ketamine: Mechanisms and relevance to treatment of depression. Annual Review of Medicine, 75, 129-143.
9. Quintanilla, B., Zarate, C. A. Jr., & Pillai, A. (2024). Ketamine's mechanism of action with an emphasis on neuroimmune regulation. Molecular Psychiatry, 29, 2849-2858.
10. Castagné, V., Moser, P., Roux, S., & Porsolt, R. D. (2011). Rodent models of depression: forced swim and tail suspension behavioral despair tests in rats and mice. Current Protocols in Neuroscience, 55(1), 8.10A.1-8.10A.14.
11. de Kloet, E. R., & Molendijk, M. L. (2021). The forced swim test: Historical, conceptual and methodological considerations and its relationship with individual behavioral traits. Neuroscience & Biobehavioral Reviews, 126, 1-19.
12. Rosso, M., Wirz, R., Loretan, A. V., Sutter, N. A., Pereira da Cunha, C. T., Jaric, I., Würbel, H., & Voelkl, B. (2022). Reliability of common mouse behavioural tests of anxiety: A systematic review and meta-analysis on the effects of anxiolytics. Neuroscience & Biobehavioral Reviews, 143, 104928.
13. Strawn, J. R., et al. (2023). Advances in pharmacotherapy for pediatric anxiety disorders. Child and Adolescent Psychiatric Clinics of North America, 32(3), 495-513.
14. Brown, K. A., & Gould, T. D. (2024). Targeting metaplasticity mechanisms to promote sustained antidepressant actions. Molecular Psychiatry, 29, 1114-1127.
15. Lullau, A., Haga, E., Ronold, E. H., & Dwyer, G. E. (2023). Antidepressant mechanisms of ketamine: a review of actions with relevance to treatment-resistance and neuroprogression. Frontiers in Neuroscience, 17, 1223145.